Is PLX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

770 people get PLX articles and Market Currents by email alert.

Get email alerts on PLX »

HEADLINES:

Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Conference

GlobeNewswire (May 8, 2013)
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

GlobeNewswire (Apr 29, 2013)
An Industry Outlook With Analyst Vernon Bernardino
Brian Nichols • Mon, Apr 22 • 5 Comments
Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease

GlobeNewswire (Apr 2, 2013)
The Future Of Medicine: A Look At 5 Stem Cell Companies
Craig Keolanui • Fri, Mar 22 • 4 Comments
UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

GlobeNewswire (Mar 18, 2013)
Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher Patients With PRX-112, an Orally-Administered Candidate for the Treatment of Gaucher Disease

GlobeNewswire (Mar 7, 2013)
Special Protocol Assessments: The Case Studies
PropThink • Fri, Feb 22 • 1 Comment
Protalix Announces New Clinical Data on ELELYSO(TM) to be Presented at the WORLD Symposium 2013

GlobeNewswire (Feb 13, 2013)
Tuesday Options Brief: PBR, PLX & XLF
Interactive Brokers • Tue, Feb 5
Protalix BioTherapeutics Reviewing Partnering and Other Alternatives

GlobeNewswire (Feb 5, 2013)
Protalix BioTherapeutics to Present at the 15th Annual BIO CEO & Investor Conference

GlobeNewswire (Feb 5, 2013)
Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium

GlobeNewswire (Jan 31, 2013)
Protalix BioTherapeutics Announces First Patient Treated in Phase I/II Study of Fabry Patients With PRX-102

GlobeNewswire (Dec 10, 2012)
Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)

GlobeNewswire (Dec 6, 2012)
Protalix BioTherapeutics to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York City

GlobeNewswire (Dec 5, 2012)
Protalix BioTherapeutics to Present at the 2012 Jefferies Global Healthcare Conference in London

GlobeNewswire (Nov 8, 2012)
European Commission Issues Decision on Taliglucerase Alfa Marketing Authorization Application

GlobeNewswire (Nov 1, 2012)
Protalix Biotherapeutics: Eyes On Elelyso Sales And Advancing Pipeline
LifeSci Advisors • Mon, Oct 1, 2012 • 4 Comments
Protalix BioTherapeutics Receives Marketing Authorization for Elelyso(TM) for the Treatment of Gaucher Disease From the Israeli Ministry of Health

GlobeNewswire (Sep 27, 2012)

To learn more about Seeking Alpha Pro, click here.

Protalix Biotherapeutics: Eyes On Elelyso Sales And Advancing Pipeline
LifeSci Advisors • Mon, Oct 1, 2012 • 4 Comments
This Biopharmaceutical Could Be Something Special
Steven Bulwa • Tue, May 8, 2012 • 9 Comments
Protalix's FDA Approval And 1-Year Price Target
Steve Johannsen • Wed, May 2, 2012 • 25 Comments
Protalix BioTherapeutics Finally Receives FDA Approval To Market Elelyso For Enzyme Replacement Therapy In Gaucher's Disease
Steven Breazzano • Tue, May 1, 2012 • 3 Comments
Protalix With Higher Chances To Get Approved After Shire's News
Joe Gantoss • Thu, Apr 26, 2012 • 10 Comments
Protalix: What You Need To Know Ahead Of The May 1 PDUFA Date
Joe Gantoss • Mon, Mar 19, 2012 • 19 Comments
Protalix's Regulatory Approval: Analyst Q&A
Ben Yoffe • Wed, Mar 7, 2012 • 1 Comment
Potentially Good Entry Point For Protalix Bio Therapeutics
BinaryLeverage • Wed, Feb 22, 2012 • 3 Comments
Protalix Reinforces Case For Taliglucerase Alfa; Healthcare Sector Volume Keeps Rising
M. E. Garza • Fri, Feb 10, 2012
Protalix BioTherapeutics: It's All About The Technology
Ben Yoffe • Tue, Jan 31, 2012 • 1 Comment
Another Catalyst For Protalix BioTherapeutics
M. E. Garza • Fri, Jan 27, 2012
Protalix BioTherapeutics: FDA Delay Provides Attractive Entry Point
Steven Breazzano • Wed, Dec 7, 2011 • 10 Comments
Protalix Biotherapeutics: Using Plants To Treat Human Disease
Market Shadows • Thu, Sep 15, 2011 • 5 Comments
Protalix BioTherapeutics: Near-Term Catalysts With Big Upside Potential
Mike Young • Sun, Sep 4, 2011 • 8 Comments
Biotech: Some CRL Recipients to Consider
Chemistfrog • Mon, May 16, 2011 • 4 Comments
What's Next for Protalix BioTherapeutics Shares Fall After FDA CRL?
Steven Breazzano • Sun, Feb 27, 2011 • 6 Comments
Conservative, Bullish Trading Strategy on Protalix Biotherapeutics' PDUFA Date
Tony Pelz • Fri, Feb 18, 2011 • 19 Comments
UBS Analyst Misses Boat With Protalix Comments
M. E. Garza • Mon, Feb 14, 2011 • 9 Comments
Insider Selling and Options Trading May Spell Troubles for Protalix
TheMarketFinancial • Wed, Feb 2, 2011 • 8 Comments
Protalix BioTherapeutics: Recent Dip Represents Attractive Entry Point
Steven Breazzano • Thu, Jan 20, 2011 • 5 Comments

An Industry Outlook With Analyst Vernon Bernardino
Brian Nichols • Mon, Apr 22 • 5 Comments
The Future Of Medicine: A Look At 5 Stem Cell Companies
Craig Keolanui • Fri, Mar 22 • 4 Comments
Special Protocol Assessments: The Case Studies
PropThink • Fri, Feb 22 • 1 Comment
Tuesday Options Brief: PBR, PLX & XLF
Interactive Brokers • Tue, Feb 5
Hedge Funds Love These 4 High-Growth Stocks Under $5
Kapitall • Thu, Sep 20, 2012 • 2 Comments
5 Highly Liquid Biotech Stocks Positively Correlated To Volatility
Kapitall • Mon, Aug 27, 2012 • 3 Comments
Pfizer Rolls On
Dividendinvestr • Mon, Aug 27, 2012 • 5 Comments
6 Cash-Heavy Biotech Stocks With Analyst Endorsements
ZetaKap • Thu, Aug 23, 2012
6 Biotech Stocks That Could Be In For A Short Squeeze
Joe Springer • Mon, Aug 20, 2012 • 7 Comments
Gaucher Disease: The Fight For Market Share
Peter Geschek • Sun, Jul 1, 2012 • 2 Comments
Opko Health: Investors Likely To Get Frostbite
Apsara Biotechnology Research • Fri, Jun 15, 2012 • 37 Comments
Medgenics Moving In Record Time
Ray Dirks • Mon, May 21, 2012 • 3 Comments
Selling An FDA Approval: Recent Results
BinaryLeverage • Wed, May 9, 2012 • 11 Comments
Pfizer Should Rise On New Gaucher Drug, Due Out In 2013
Vatalyst • Mon, May 7, 2012 • 2 Comments
Apple, Intel, Protalix: Learning Lessons With Options
Rocco Pendola • Wed, May 2, 2012 • 10 Comments
Wednesday Options Recap
Frederic Ruffy • Wed, May 2, 2012
Will We Hold It Wednesday: Now It's May
Philip Davis • Wed, May 2, 2012 • 1 Comment
Wednesday's Bio Pharma Drug Approval And Catalyst Watch List
Scott Matusow • Wed, May 2, 2012 • 15 Comments
12 Healthcare Companies Expecting May Catalysts
Spencer Knight • Tue, May 1, 2012 • 9 Comments
Biotechs On The Move For Today
Scott Matusow • Wed, Apr 25, 2012 • 30 Comments

There are no Transcripts on PLX.

Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Conference

GlobeNewswire (May 8, 2013)
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

GlobeNewswire (Apr 29, 2013)
Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease

GlobeNewswire (Apr 2, 2013)
UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

GlobeNewswire (Mar 18, 2013)
Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher Patients With PRX-112, an Orally-Administered Candidate for the Treatment of Gaucher Disease

GlobeNewswire (Mar 7, 2013)
Protalix Announces New Clinical Data on ELELYSO(TM) to be Presented at the WORLD Symposium 2013

GlobeNewswire (Feb 13, 2013)
Protalix BioTherapeutics Reviewing Partnering and Other Alternatives

GlobeNewswire (Feb 5, 2013)
Protalix BioTherapeutics to Present at the 15th Annual BIO CEO & Investor Conference

GlobeNewswire (Feb 5, 2013)
Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium

GlobeNewswire (Jan 31, 2013)
Protalix BioTherapeutics Announces First Patient Treated in Phase I/II Study of Fabry Patients With PRX-102

GlobeNewswire (Dec 10, 2012)
Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)

GlobeNewswire (Dec 6, 2012)
Protalix BioTherapeutics to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York City

GlobeNewswire (Dec 5, 2012)
Protalix BioTherapeutics to Present at the 2012 Jefferies Global Healthcare Conference in London

GlobeNewswire (Nov 8, 2012)
European Commission Issues Decision on Taliglucerase Alfa Marketing Authorization Application

GlobeNewswire (Nov 1, 2012)
Protalix BioTherapeutics Receives Marketing Authorization for Elelyso(TM) for the Treatment of Gaucher Disease From the Israeli Ministry of Health

GlobeNewswire (Sep 27, 2012)
Protalix BioTherapeutics to Present at the UBS Global Life Sciences Conference

GlobeNewswire (Sep 12, 2012)
Protalix BioTherapeutics Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients With PRX-102, a Modified Enzyme Replacement Therapy

GlobeNewswire (Aug 13, 2012)
Protalix BioTherapeutics to Present at the Canaccord Genuity 32nd Annual Growth Conference

GlobeNewswire (Aug 9, 2012)
Video: Using Plants to Make Cheaper Biotech Drugs

at MarketWatch.com (Jul 9, 2012)
New Clinical Data on ELELYSO(TM) (taliglucerase alfa) to be Presented at the 10th Annual European Working Group on Gaucher Disease Meeting

GlobeNewswire (Jun 25, 2012)

PLX vs. ETF Alternatives

Company Description

We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellExTM protein expression system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary and biosimilar or... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, April 29, 8:18 AM Protalix BioTherapeutics (PLX) rises 6% premarket as its Type I Gaucher disease treatment UPLYSO ("ELELYSO" outside of Latin America) gains approval in Mexico and Chile — it is already approved in the U.S., Israel, and Brazil. The company develops and commercializes the drug with Pfizer (PFE). (PR) Comment! [Healthcare, On the Move]
Tuesday, April 2, 8:08 AM Protalix BioTherapeutics (PLX) says the first patient has been treated in a phase 1 clinical trial of its orally-administered treatment for Gaucher disease. The phase 1 trial should be completed during Q3 of this year. Shares +1.5% premarket. Comment! [Healthcare]
Monday, March 18, 3:22 PM Protalix BioTherapeutics (PLX +2.3%) reverses morning losses to gain on news that Brazilian health authorities had given regulatory approval to Uplyso, a long-term enzyme replacement therapy for adults with Type I Gaucher disease. PLX has partnered with Pfizer (PFE +0.3%) to market and commercialise the drug worldwide, apart from Israel where it maintains exclusive rights. Comment! [Healthcare, On the Move, Global & FX]
Tuesday, February 5, 1:00 PM Midday top 10 gainers: OPXA +189%. CEP +31%. SCKT +23%. PLX +18%. CPSS +18%. VMED +17%. TRT +17%. STV +16%. BCOM +15%. CNR +15%.
Midday top 10 losers: DCIX -13%. IEC -13%. PRPH -11%. BIDU -11%. ACI -11%. PGRX -10%. JAXB -10%. DFZ -10%. RTEC -9%. SGMS -9%. Comment! [On the Move]
Tuesday, February 5, 9:44 AM Protalix (PLX) surges 14.2% following an Israeli report that Pfizer has shown an interest in buying the company after it hired Citigroup to start a sale process. Protalix is angling for $1B, double its market cap, although Pfizer doesn't want to pay that much, while an offer of $700-800M could be enough to sway Protalix's largest shareholders. The companies already partner for the marketing of Protalix's Elelyso drug for Gaucher disease. Comment! [Healthcare, On the Move, M&A]
Monday, December 10, 2012, 10:24 AM Protalix BioTherapeutics (PLX +0.7%) says its the first patient has been treated in its Phase I/II clinical trials of PRX-102, its plant cell-expressed, chemically modified enzyme replacement therapy for the treatment of Fabry disease. Comment! [Healthcare, On the Move]
Thursday, December 6, 2012, 8:33 AM Protalix (PLX +5.5%) signs an agreement with Pfizer (PFE) in which the latter will conduct and sponsor new trials for Protalix's Elelyso treatment for Gaucher disease, which stops cells and organs from working properly. Protalix will be eligible to receive milestone payments of up $8.3M; the company will continue to conduct existing trials of Elelyso. (PR) 3 Comments [Healthcare, On the Move]
Monday, June 25, 2012, 10:49 AM Protalix (PLX -3.7%) slips after being downgraded to Market Perform at Wells Fargo, citing the CHMP's rejection of Elelyso - despite the drug's favorable benefits - in deference to Shire's Orphan exclusivity status for Vpriv. The firm also lowers its price range to $6 - $8 from $9 - $11. Comment! [Healthcare, On the Move]
Friday, June 22, 2012, 9:26 AM Protalix Biotherapeutics (PLX) -16.7% premarket after saying European medical authorities have ruled against recommending taliglucerase alfa, an enzyme replacement therapy for treatment of Gaucher disease developed by PLX and its partner Pfizer (PFE). Comment! [Healthcare, On the Move]
Friday, June 22, 2012, 9:10 AM Premarket gainers: HNR +82%. ALXA +19%. NPSP +9%.
Losers: PLX -12%. R -10%. 2 Comments [On the Move]
Wednesday, May 2, 2012, 12:14 PM Canaccord takes some of the shine off Protalix's (PLX +13%) early morning 27% run-up in the wake of the FDA's approval of its new treatment for Gaucher disease, downgrading the shares to Hold after digging deeper into the report. The firm says it sees only modest U.S. but solid Israel/ROW potential, and EU approval may in fact be blocked. Comment! [Healthcare, On the Move]
Wednesday, May 2, 2012, 9:00 AM Premarket gainers: SMSC +38%. CHRS +24%. PLX +22%. TRIP +16%. ASNA +13%. PCO +13%. ESIC +13%. AEO +9%. DCIX +8%. WCG +9%. OCZ +8%. HLF +6%. GNW +4%. REXX +3%. CBS +3%. UBS +3%.
Losers: OPEN -15%. CHK -10%. STD -7%. VE -5%. TEF -5%. CS -5%. NOK -4%. TS -4%. DB -4%. NBG -4%. CMCSA -4%. FTE -3%. ERIC -3%. SI -3%. Comment! [On the Move]
Tuesday, May 1, 2012, 4:32 PM Protalix BioTherapeutics (PLX) +22.8% AH after the FDA approves the company's new orphan drug to treat a form of Gaucher disease. Comment! [Healthcare, On the Move]
Monday, April 30, 2012, 9:10 AM Premarket gainers: BKS +92%. DMD +38%. SUN +21%. WCRX +20%. GPRO +20%. XOMA +9%. IOC +5%. MNKD +5%. PLX +4%. ARNA +4%. AMRN +3%.
Losers: LDK -14%. SOHU -8%. GNC -5%. HUM -5%. HOLX -4%. SINA -3%. Comment! [On the Move]
Monday, April 23, 2012, 9:05 AM Premarket gainers: RDEA +51%. CEDC +20%. KERX +16%. AMLN +12%. PLX +5%.
Losers: ACHN -14%. ING -7%. CHKP -6%. MT -5%. MT -5%. DB -5%. WMT -5%. AKS -4%. RIO -4%. FSLR -4%. BAC -4%. EPI -4%. TOT -3%. ERIC -3%. NG -3%. FCX -3%. TEF -3%. F -3%. CS -3%. MS -3%. X -3%. RVBD -3%. AMD -3%. 1 Comment [On the Move]
Thursday, February 16, 2012, 12:44 PM Protalix BioTherapeutics (PLX -10.6%) says its sale of 4.5M shares priced at $5.25 per share, a 14% discount to yesterday's close. Comment! [Healthcare, On the Move]

Joseph P. Porter
Could $PLX be on $PFE's shopping list? They have partnered, and $PLX is speculated as acquisition fodder. It would cost $PFE pocket money.
Feb 8, 1:11 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Cash-Heavy Biotech Stocks With Analyst Endorsements http://bit.ly/TXLKnB $CYTX $PLX $GTXI $HALO $ILMN $THRX @ZetaKap
8/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

nonameseekingalpha
Bought PLX @5.71 was this a good idea? Was it close to breaking even or will managment never let the stock run even if it does run a profit?
8/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Robbster
PSTI, baby. Will be very very successful. Read the article on intramuscular delivery of PLX cells... signpost on road to success says I...
6/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Steven Bulwa
Impressed with $PLX approval, very interesting technology with broad applications. Reminds me of $CRXL. May dip a toe in after hours.
5/1/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: I agree with PLX, but IBIO looks like a more valuable and efficient better play
5/1/12
• !Report Abuse
Steven Bulwa: $IBIO intrigues but there is something about an approved drug and $PFE in your corner that appeals to me more. Good luck.
5/1/12
• !Report Abuse
Add a reply...

140 characters

iadops40
IBIO up 29% in after hours trade riding PLX's FDA approval http://bloom.bg/KFVaSh
5/1/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: yeah, but for those who bought on the dip will make off like bandits. Could rally up to $2.00 in the short term.
5/1/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$IBIO up $0.18, 12%, $PLX up $0.55 7.91% in after hour trading.
5/1/12
Reply (11)

• !Report Abuse
View all 11 replies
iadops40: Thanks Scott, I know you are a busy guy. I am also curious if you have any insight or plans to cover PPHM, good pipeline
5/2/12
• !Report Abuse
mofisher22: Scott, good news ibio, thanks for your pr, looks like dvax, hep drug, is great buy out potential. Let me know how dd is going on NVIV
5/2/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$PLX's Taliglucerase approved. stock rallying, also rallying is $IBIO
5/1/12
Reply (6)

• !Report Abuse
View all 6 replies
0123456789: YES!
5/1/12
• !Report Abuse
0123456789: YES!
5/1/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$IBIO is a developmental stage co. tons of potential, 62M market cap and there is a catalyst tied into $PLX, play for the pop to come
4/5/12
Reply (3)

• !Report Abuse
View all 3 replies
Scott Matusow: my take is basically as I have always said on SPPI; it is a long term investment. Management top notch, typical short term market poop
4/5/12
• !Report Abuse
GaryLee276: Good. I got 1000 more at $10.71.
4/6/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$IBIO also has a catalyst run up tied to $PLX, target = $1.80
4/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Dog of times
Buys: ING, AIG, PLX, OPTT, ELON, CHNG.PK, BWEN. Sales: GSK, XIDE, SLT. Sales, were trailing stop loss types with good gains. Buys are stopped.
12/5/09
Reply (1)

• !Report Abuse
View all 1 replies
117746: Tell me smething about ECHELON after sept 07,2007 until today has drop more than 90% why? today again funny play too low.
12/20/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$IBIO up $0.18, 12%, $PLX up $0.55 7.91% in after hour trading.
5/1/12
Reply (11)

• !Report Abuse
View all 11 replies
iadops40: Thanks Scott, I know you are a busy guy. I am also curious if you have any insight or plans to cover PPHM, good pipeline
5/2/12
• !Report Abuse
mofisher22: Scott, good news ibio, thanks for your pr, looks like dvax, hep drug, is great buy out potential. Let me know how dd is going on NVIV
5/2/12
• !Report Abuse
Add a reply...

140 characters

iadops40
IBIO up 29% in after hours trade riding PLX's FDA approval http://bloom.bg/KFVaSh
5/1/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: yeah, but for those who bought on the dip will make off like bandits. Could rally up to $2.00 in the short term.
5/1/12
• !Report Abuse
Add a reply...

140 characters

Steven Bulwa
Impressed with $PLX approval, very interesting technology with broad applications. Reminds me of $CRXL. May dip a toe in after hours.
5/1/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: I agree with PLX, but IBIO looks like a more valuable and efficient better play
5/1/12
• !Report Abuse
Steven Bulwa: $IBIO intrigues but there is something about an approved drug and $PFE in your corner that appeals to me more. Good luck.
5/1/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$PLX's Taliglucerase approved. stock rallying, also rallying is $IBIO
5/1/12
Reply (6)

• !Report Abuse
View all 6 replies
0123456789: YES!
5/1/12
• !Report Abuse
0123456789: YES!
5/1/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$IBIO is a developmental stage co. tons of potential, 62M market cap and there is a catalyst tied into $PLX, play for the pop to come
4/5/12
Reply (3)

• !Report Abuse
View all 3 replies
Scott Matusow: my take is basically as I have always said on SPPI; it is a long term investment. Management top notch, typical short term market poop
4/5/12
• !Report Abuse
GaryLee276: Good. I got 1000 more at $10.71.
4/6/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
Check out upcoming Fda approval Dates http://bit.ly/H6kqQR $ARNA, $RGEN, $XNPT, $SLXP, $GILD, $ALXA, $PLX,$VVUS, $AMGN,$FURX,$CTIC,$VRTX
4/1/12
Reply (3)

• !Report Abuse
View all 3 replies
freefdawatchlist: don't buy more, because if fda delay it by 3 month, the stock may drop. Check out other stock which haven't rallied up till now.
4/1/12
• !Report Abuse
phemale60: VVUS's Avanafil up for FDA approval late April also. Any info about it? I appreciate your insight!
4/1/12
• !Report Abuse
Add a reply...

140 characters

PLX Protalix BioTherapeutics, Inc

PLX

Protalix BioTherapeutics, Inc